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Obsessive–compulsive disorder (OCD) is a neuropsychiatric disorder affecting approxi-
mately 1–3% of the population. OCD is probably an etiologically heterogeneous condi-
tion. Individuals with OCD frequently have additional psychiatric disorders concomitantly
or at some time during their lifetime. Recently, some authors proposed an OCD sub-
classification based on comorbidity. An important issue in assessing comorbidity is the
fact that the non-response to treatment often involves the presence of comorbid condi-
tions. Non-responsive patients are more likely to meet criteria for comorbid axis I or axis
II disorders and the presence of a specific comorbid condition could be a distinguishing
feature in OCD, with influence on the treatment adequacy and outcome.
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INTRODUCTION
Obsessive–compulsive disorder (OCD) is a neuropsychiatric dis-
order affecting approximately 1–3% of the population and it
is characterized by recurrent intrusive ideas, impulses, or urges
(obsessions) along with overt or covert behaviors (compulsions)
aimed at reducing the distress (Karno et al., 1988; DSM-IV).
Obsessive–compulsive disorder was initially considered as a
sub-dimension of depression, the so-called “ananchastic depres-
sion.” In the 1980s this concept was questioned, demonstrat-
ing that only antidepressants with serotonin-reuptake inhibition
activity were effective in treating obsessions and compulsions.
In the last years, there has been another important paradigm
shift, including other neurotransmittorial systems in the puta-
tive pathophysiological mechanisms underlying OCD, such as
dopamine, glutamate, noradrenaline, and GABA. This leads to
the crucial hypothesis that OCD may be an etiologically hetero-
geneous condition, therefore being affected by a wide spectrum
of comorbidities. Individuals with OCD frequently have addi-
tional psychiatric disorders concomitantly or at some time during
their lifetime (Angst et al., 2005). Recently, some authors proposed
an OCD sub-classification based on comorbidity (Nestadt et al.,
2009). The authors proposed a three classes solution character-
ized by: (1) an OCD simplex class, in which major depressive
disorder (MDD) is the most frequent additional disorder; (2)
an OCD comorbid tic-related class, in which tics are promi-
nent and affective syndromes are considerably rarer; and (3)
an OCD comorbid affective-related class in which panic disor-
der (PD) and affective syndromes are highly presented (Nestadt
et al., 2009). Membership within a class is differentially associ-
ated with other clinical characteristics. For example, the OCD
comorbid tic-related class is predominantly male and charac-
terized by high consciousness. The OCD co-morbid affective-
related class is predominantly female, has a young age at onset,
obsessive–compulsive personality disorder features, high score
on the “taboo” factor of OCD symptoms, and low conscious-
ness.
An important issue in assessing comorbidity is the fact that
non-response to treatment often involves the presence of comor-
bid conditions. Non-responsive patients are more likely to meet
criteria for comorbid axis I or axis II disorders and the presence
of a specific comorbid condition could be a distinguishing feature
in OCD, with influence on the treatment adequacy and outcome
(Pallanti and Quercioli, 2006). Particularly, comorbid conditions
such as bipolar disorder (BD) and attention deficit hyperactivity
disorder (ADHD) are common in treatment-resistant patients, but
there are only few studies investigating their impact on treatment
resistance (Magalhães et al., 2010; Sheppard et al., 2010).
The aim of this paper is to discuss clinical characteristics of
OCD comorbidities and their implication in the management
of OCD patients. We will review only the most clinical relevant
comorbidities.
METHOD
In this paper we present a systematic review of papers focusing
on OCD comorbidities. Data were extracted from published arti-
cles from the Medline database until May 2011. The keywords
used for the research were various combinations of the following
words: OCD, OCD comorbidities, BD, MDD, psychosis, ADHD,
PD, social phobia, post-traumatic stress disorder (PTSD), epilepsy,
stroke.
OCD AND MOOD DISORDERS
Epidemiology
Recent epidemiological and clinical studies confirmed the pres-
ence of a strong association between OCD and affective disorders
(Kruger et al., 1995; McElroy et al., 2001).
The association between OCD and depression has been
acknowledged since the nineteenth century (McIntyre et al., 2006).
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Depression is the most frequent complication of OCD, as reported
in several studies (El-Mallakh and Hollifield, 2008).
Denys et al. (2004) found that MDD was 10 times more preva-
lent in OCD patients than in general population. While up to
60–80% of patients with OCD experience a depressive episode in
their lifetime, most studies agree that at least one-third of patients
withOCDhave concurrentMDDat the time of evaluation (Perugi
et al., 1997; Tükel et al., 2002).
Comorbidity rates in reported studies vary widely from 19 to
90%; this is largely due tomethodological and semantic differences
(Overbeek et al., 2002).
Obsessive–compulsive morbidity is also one of the most dis-
abling co-occurring conditions in bipolar disease (BD), and
these symptoms are frequently encountered in clinical practice
(El-Mallakh and Hollifield, 2008).
Bipolar comorbidity in obsessive–compulsive disorder (OCD)
is a relevant phenomenon and has clinically significant influence
on the symptomatological expression and complications of the
disorder (D’Ambrosio et al., 2010).
Moreover, comorbidity with BD has relevant implications for
treatment outcome, since bipolarity has a negative influence on
compliance and response to currently available anti-obsessive
agents (Krüger et al., 2000; Perugi et al., 2002; Hantouche et al.,
2003).
A recent study individuated OCD as the most frequent anxiety
disorder in bipolar patients throughout their lifetime (Zutshi et al.,
2006).
In adults, evidence of a higher-than-expected overlap between
OCD and BPD first came from the Epidemiological Catchment
Area study, where 23% of those with BPD also met criteria for
OCD (Robins and Price, 1991). Subsequent studies have consis-
tently found a greater than expected overlap between OCD and
BPD at rates as high as 15–35% (Joshi et al., 2010).
Clinical and epidemiological studies in recent years have sug-
gested that the rate of lifetime comorbid BD in clinical and
epidemiological samples of patients with obsessive–compulsive
disorder (OCD) is up to 21.5% (Perugi et al., 1997; Hantouche
et al., 2003; Faravelli et al., 2004).
In addition, many authors have concluded that the frequency
of OCD is higher in bipolar patients than in general population
(9–35% versus 1.5–2.3%;Cassano et al., 1999;McElroy et al., 2001;
Simon et al., 2004). On the other hand, certain studies do not sup-
port these high rates of comorbidity (Vieta et al., 2001;Henry et al.,
2003).
Family members of bipolar I and II affected individuals have
higher rates of OCD (Coryell et al., 1985), which suggests a
familial or genetic association. However, some researchers believe
that obsessive–compulsive symptoms (OCS), particularly when
episodic, may actually represent a variation of how bipolar illness
is expressed and not a true comorbidity (Strakowski et al., 1998;
Swartz and Shen, 1999).
Whenusing awider concept of bipolar spectrum inboth clinical
and epidemiological studies, lifetime comorbidity rates increased
significantly: almost 50%of OCDcasesmanifest cyclothymic traits
and/or some lifetime hypomanic symptoms (Hantouche et al.,
2003).
Clinical characteristics and clinical course
The comorbidity of OCD and affective disorders strongly affects
clinical features, treatment outcome, and prognosis of such
patients.
As for the comorbidity withMDD, it is reported thatmost often
OCD predates depression, suggesting that depressive symptoms
usually occur in response to the distress and functional impair-
ment associated with OCD (Ricciardi and McNally, 1995; Bartz
and Hollander, 2006).
In addition, depressive symptoms seem to be more strongly
associated with obsessive than with compulsive symptoms (Ric-
ciardi and McNally, 1995).
The presence of comorbid MDD in OCD seems to relate to
older age, severity and chronicity of OCS, number of hospital-
izations, greater comorbidity with generalized anxiety disorder
(GAD), simple phobias and caffeine abuse, higher frequency of
aggressive obsessions, higher number of suicide attempts, and
disability (Perugi et al., 2002; Tükel et al., 2006;Maina et al., 2007).
The clinician should also accurately investigate obsessive symp-
toms anddifferentiate it from ruminations,which are typically and
exclusively focused on depressive thematics, but may sometimes
appear similar in their clinical presentation.
The comorbidity of BD in OCD has relevant implications on
the symptomatological expression and pharmacological treatment
of the disorder.
Obsessive–compulsive disorder and BPD comorbidity in adults
may herald an episodic course of OCD with higher rates of certain
obsessions (aggressive/impulsive, sexual, religious, andobsessional
doubts) and compulsions (compulsions of control, hoarding,
ordering/arranging), which require more frequent hospitaliza-
tions and complex pharmacological interventions (Hantouche
et al., 2003; Millet et al., 2004; Maina et al., 2007).
Bipolar subjects with OCD were more likely than those without
OCD to have higher lifetime rates of thoughts of death and suicide
and of suicide attempts (Freeman et al., 2002).
Furthermore, subjects with OCD and comorbid BD have
higher rates of panic/agoraphobia, substance use disorders, and
higher rates of narcissistic and antisocial personality disorders
(Hantouche et al., 2003; Millet et al., 2004; Maina et al., 2007).
Similarly, the presence of OCD comorbidity has been reported
to predict a more chronic course of BPD and greater frequency of
major depressive episodes, with a trend toward poor response to
mood stabilizers (Perugi et al., 2002; Zutshi et al., 2006)
Zutshi et al. described bipolar patients with a comorbid anxi-
ety disorder as younger,mostly male, having earlier ages of disease
onset, and higher rates of academic failure. These patients also
have poor treatment response, higher rates of psychotic features,
mixed episodes, suicide attempts, and substance abuse, more fre-
quent hospitalizations, and a higher percentage of time spent in
illness episodes (Cassano et al., 1999; Simon et al., 2004; Zutshi
et al., 2006).
Some investigators have observed that OCD symptoms may
vary during the course of BD. For example, cases have been
reported in which OCD symptoms remitted during mania and
reappeared with the remission of it and/or onset of depression
(Keck et al., 1986; Gordon and Rasmussen, 1988). In addition,
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authors have noted that patients with mixed mania may be more
likely than patients with pure mania to have comorbid OCD
(McElroy et al., 2001).
Treatment
The therapeutic implications of a comorbid depressive disorder in
OCD are still poorly understood. Comorbidity affects the out-
come of behavioral versus pharmacotherapeutic interventions.
For example, in OCD, severe depression may worsen the prognosis
for behavioral treatments, whereas most studies suggest that phar-
macological treatment with selective serotonin reuptake inhibitors
(SSRIs) is equally effective for OCD with or without concomitant
depression (Overbeek et al., 2002).
Meta-analytic studies have shown that the beneficial effects
of antidepressants such as clomipramine and SSRIs on OCD
symptoms are unrelated to the presence of depressive symptoms.
Hollander et al. (1991) state that depressive symptoms interfere
with the response to both psychopharmacologic and behavioral
treatments of OCD. Also, Foa (1979) reported that the outcome
of behavioral therapy is negatively influenced by the presence of
severe depressive symptoms.
However, although comorbid depressive disorder might alter
treatment outcome, it has little impact on the psychopharmaco-
logical strategy, as serotonin reuptake inhibitors (SRI) are first line
treatment for both conditions.
Instead, the comorbidity of OCD with BD is a difficult ther-
apeutic challenge because the pharmacological treatments of the
two illnesses diverge and medications used to manage OCD can
exacerbate BD symptoms.
The centerpiece of pharmacologic treatment of OCD is the use
of the serotoninergic antidepressants and these agents have repeat-
edly demonstrated both acute and prophylactic efficacy and are
currently consideredfirst line agents (Pallanti et al., 2002;Hollifield
et al., 2006).
Unfortunately, the use of antidepressants may be problematic
in bipolar illness. Specifically, antidepressants may induce manic
episodes, destabilize the illness over time by increasing the num-
ber of both manic and depressive episodes, or induce a chronic
depressive state (El-Mallakh and Karippot, 2005, 2006).
A small amount of controlled data is available concern-
ing the treatment of BD complicated by OCD. However, ade-
quate mood stabilization should be achieved before antidepres-
sants are used to treat OCD symptoms in order to minimize
antidepressant-induced mania or cycling (Freeman et al., 2002).
In the past years, reports have pointed out a potential role for
atypical antipsychotics (AAP) in the treatment of OCD that is
resistant to SRI. In particular, there is positive evidence for risperi-
done, haloperidol, olanzapine, and quetiapine (Goodwin et al.,
2009).
Reviews and meta-analyses of randomized controlled tri-
als suggest the efficacy of aripiprazole in the acute treat-
ment and maintenance treatment of manic episodes. More-
over, adjunctive aripiprazole seems to be effective in improv-
ing response rate in patients with MDD. Some studies sug-
gest a role for aripiprazole in the treatment of OCD. These
reports include aripiprazole augmentation of SRI in treatment-
resistant OCD, or in patients with schizophrenia comorbid
OCS (Glick et al., 2008; Arbaizar et al., 2009; McIntyre,
2010).
Mood stabilizers may also have an effect in OCD but have not
been extensively studied (El-Mallakh and Hollifield, 2008). While
these agents are second line choices for the treatment of OCD
patients without bipolar illness, they become usually first line
agents in bipolar subjects. However, they are generally subopti-
mal in the control of anxiety symptoms and carry a higher side
effects burden than serotoninergic antidepressants (El-Mallakh
and Hollifield, 2008). Non-pharmacologic approaches, such as
cognitive behavioral psychotherapy (CBT) and transcranial mag-
netic stimulation may have an important role, which should be
formally tested in this situation (Magalhães et al., 2010). Raja
et al. suggest that, from a therapeutic point of view, it should
be given hierarchical priority of a bipolar diagnosis even when
the criteria for a DSM-IV-TR OCD diagnosis are fully met and
when bipolar symptoms are sub-threshold. Whatever the inten-
sity of OCD symptoms, current, or past presence of signs or
symptoms consistent with BD, or a familial load for BD, should
suggest caution in prescribing SSRI treatment (Raja and Azzoni,
2004).
They propose as a safer first line choice a treatment with
mood stabilizers (lithium plus anticonvulsants, or electroconvul-
sive therapy). In some patients, especially those who manifest
psychotic symptoms, a combination of mood stabilizers, and
second-generation antipsychotics is required. Even if AAP have
sometimes been reported to exacerbate OCD symptoms, these
drugs are effective in the treatment of OCD symptoms in bipolar
spectrum–OCD patients (Raja and Azzoni, 2004).
Mood stabilization should be achieved as a first objective.
In unresponsive patients, addition of low doses of SSRI could
be considered, while strictly monitoring emerging symptoms of
(hypo)mania ormixed states. In some cases, the best optionmaybe
to look for a reasonable compromise between potential anti-OCD
effectiveness and detrimental effect on OCD (Raja and Azzoni,
2004).
OCD AND PSYCHOSIS
Epidemiology
The relationship between OCD and psychosis has been a matter
of dispute for many years. The first description of OCD in psychi-
atric literature by Jeremy Taylor in the mid-seventeenth century
was a patient with intrusive thoughts that developed into paranoid
delusion (Hunter and MacAlpine, 1963). Co-occurrence of OCS
and psychotic disorders was first recognized over a century ago
(Berrios, 1989). Recently, interest in this area has increased con-
siderably, probably due to the recognition of higher-than-expected
comorbidity rates and the observation of emergence, or exacerba-
tion, of OCS during treatment with AAP. (Ghaemi et al., 1995;
Khullar et al., 2001; de Haan et al., 2002; Lykouras et al., 2003;
Alevizos et al., 2004).
There is growing evidence that patients with comorbid OCD
and schizophrenia (recently termed “schizo-obsessive”; Hwang
and Hollander, 1993; Zohar, 1997) appear to have distinct patterns
of psychopathology, course of illness, psychiatric comorbidity,
neurocognitive deficits, and treatment response, compared to their
schizophrenic counterparts, suggesting the existence of a separate
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subgroup on the schizophrenia spectrum (Poyurovsky et al., 2004;
Lysaker and Whitney, 2009).
The prevalence of comorbid OCD and schizophrenia was esti-
mated at 12.2% by the US National Institute for Mental Health
Epidemiologic Catchment Area Study (Karno et al., 1988). Recent
studies reported that approximately 8–26% of schizophrenic
patientsmet theDSM-IV criteria forOCD(Eisen et al., 1997; Porto
et al., 1997; Poyurovsky et al., 1999, 2001; Bermanzohn et al., 2000;
Tibbo et al., 2000; de Haan et al., 2002; Nechmad et al., 2003; Ohta
et al., 2003; Byerly et al., 2005). However, other investigators have
reported rates up to 59.2% (Bland et al., 1987). A common bias in
these estimates of comorbidity lies in the enrollment of patients
with OCS and not strictly OCD. Obviously, when patients with
OCS are included, the true comorbidity of OCD and psychosis
may be grossly overestimated. However, the two conditions appear
to co-occur more commonly than their lifetime prevalence rates
of 1–1.5% and 2–3%, respectively, suggest. Finally, several studies
investigating OCD comorbidity reported that 10–60% of schizo-
phrenic patients have OCS (Fenton and McGlashan, 1986; Bland
et al., 1987; Berman et al., 1995a, 1998; Lysaker et al., 2000; Okasha
et al., 2000; Fabisch et al., 2001; Kayahan et al., 2005).
Clinical characteristics and clinical course
In a clinical perspective, differentiating an obsession from a delu-
sion represents a difficult but important challenge because of its
impact on the choice of treatment. Difficulty is due to the fact
that assessment of insight alone can not resolve the distinction
between an obsession and a delusion. Indeed, the Diagnostic and
Statistical of Mental Disorders, fourth edition (DSM-IV), allows
for the diagnosis of OCD with the specifier “with poor insight.”
So in front of an obsession with poor insight the differential diag-
nosis of delusion should be based on other criteria. Bottas et al.
(2005) in their review of the schizo-obsessive subtype of schizo-
phrenia gave six suggestions to identify OCS in the schizophrenic
patient. The first suggestion is that the types of obsessions and
compulsions observed in schizophrenia are phenomenologically
similar to those present in pure OCD. According to this observa-
tion, a recent study identified five Y-BOCS symptom dimensions
in schizophrenic patients that did not correlate with schizophrenia
symptom dimensions and that were comparable to those revealed
in “pure” OCD (Faragian et al., 2009).
With regards to behavioral assessment it is important to under-
line that a repetitious act or behavior should be considered a
compulsion only if it occurs in response to an obsession and
not if it occurs in response to psychotic ideation (e.g., repeti-
tive checking in response to paranoid fears does not constitute
a compulsion). In the same way, the clinician should differenti-
ate between compulsions and simple motor stereotypies, which
are repetitive or ritualistic movement or postures, automatic, pat-
terned, and periodic, but that not take place in order to relieve
anxiety and obsessive thoughts.
In the assessment of thought disorders the authors sug-
gest to not consider a recurrent, intrusive, ego-dystonic thought
as an obsession if it revolves exclusively around current delu-
sional themes (e.g., violent images, which constitute a common
type of obsession in OCD, may represent an entirely different
phenomenological entity in the context of psychosis).
Similarly, there are other conditions in which we must exercise
caution in the evaluation of OCS. Indeed, OCS may be difficult to
distinguish in the presence of thought form disorder. Neverthe-
less, primary obsessional slowness may be mistaken for prodromal
schizophrenia or thought disorder; such patients may be unable to
articulate any obsessions and may exhibit no compulsions. Finally,
at times it may not be possible to determine if apparent OCS in
the presence of psychosis represent real OCS; in such cases empiric
treatment with a neuroleptic and a serotonin reuptake inhibitor
(the standard treatment for OCD) may be necessary (Bottas et al.,
2005).
Classically, early investigators argued that OCS might precede
the onset of schizophrenia because they could retard or prevent
the“personality disintegration”associatedwith psychosis (Stengel,
1945).
Several studies investigated the onset of OCD in schizophrenic
patients; in these studies the onset of OCD preceded or co-
occurredwith theonset of schizophrenia in 47–76%and succeeded
schizophrenia onset in only 23–25% of patients (Poyurovsky et al.,
2003, 2008). Furthermore,OCS and OCD seem to be frequent also
in the UHR (ultra high risk syndrome); indeed, a recent investiga-
tion found a prevalence of OCD of 14–20% in a sample of UHR
youth (Niedman et al., 2009).
Compared with schizophrenic patients, schizo-obsessive
patients show a different pattern of comorbidity, with a pref-
erential aggregation of OCD–spectrum disorders, namely body
dysmorphic disorder, eating disorders, and tic disorders, but not
major depressive, substance abuse,or anxiety disorders (Poyurosky
et al., 2006).
A fairly large number of studies have assessed, as a primary
or a secondary aim, the impact of OCS or OCD on the severity
of psychotic symptoms, and on the general outcome in schizo-
phrenic patients. Taken individually, these studies have yielded
heterogeneous results. Recently, a meta-analysis of these stud-
ies, including 1096 patients, showed that the impact of OCS and
OCD on the severity of psychotic symptoms was dependent on the
definition of OCS. When a categorical definition was used, no dif-
ferences were found between OCD–schizophrenia and non-OCD
schizophrenia, whereas when a dimensional definition was used,
OCS–schizophrenia showed a greater severity of psychotic symp-
toms than non-OCS schizophrenia (Cunill et al., 2009). These
findings suggest the possibility that comorbidity with OCD in
schizophrenia differs from schizophrenia exhibiting OCS with-
out the diagnosis of OCD. Accordingly, a recent Japanese study,
found that schizophrenic patients with OCS exhibited signifi-
cantly earlier onset of schizophrenia, lower socioeconomic sta-
tus, and more severe psychiatric symptoms than those without
OCS. Earlier hospitalizations, familiar history of psychosis, more
severe schizophrenic symptoms,were associatedwithOCS comor-
bidity. Moreover, negative symptoms were associated with OCD
comorbidity in chronic schizophrenia (Owashi et al., 2010).
The data regarding the influence of OCD comorbidity on sui-
cide risk are controversial. Recently, two studies reported that these
patients have more suicidal ideation and a higher rate of suicide
attempts compared to those without OCD (Ucok et al., 2006;
Sevincok et al., 2007). However other studies failed to find this
association (Ucok et al., 2011).
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Cognitive and neuropsychological impairment in schizo-
obsessive and schizophrenic patients has been investigated in
several studies, but results are often inconsistent. Pallanti et al.
(2009) conducted the first neurophysiological examination com-
paring schizo-OCDwithOCD,schizophrenic patients, andhealthy
controls. Schizo-OCD showed a distinct event-related potential
pattern (intermediate between that of OCD and schizophrenic
patients) suggesting the presence of a less functional impairment
in schizo-OCD compared to schizophrenic patients and arguing
that schizo-OCD may not only be a distinct clinical entity from
pure OCD and schizophrenia, but it may also be characterized by
a distinguishable neurophysiologic pattern (Pallanti et al., 2009).
Treatment
Evidence regarding therapeutic options for treating OCD and
OCS in schizo-obsessive patients is limited and treatment itself
represents a major challenge because of the emerging evidence
of AAP-induced OCS. Since the introduction of AAP, both case
reports (Diler et al., 2003; Lykouras et al., 2003; Alevizos et al.,
2004; Ke et al., 2004; Ozer et al., 2006; Stamouli and Lykouras,
2006) and clinical studies (Baker et al., 1992; de Haan et al., 1999;
Ertugrul et al., 2005) have described de novo onset of OCS dur-
ing treatment with these drugs. Conventional neuroleptics with
high D2-blocking potency, such as haloperidol and pimozide, do
not seem to worsen OCD while the lower potency conventional
neuroleptic chlorpromazine induced OCS in two patients (How-
land, 1996). Most reports of APP-induced OCS in schizophrenic
patients are related to clozapine, risperidone, olanzapine, and que-
tiapine (Ghaemi et al., 1995; Baker et al., 1996; Khullar et al., 2001;
Reznik et al., 2004; Tranulis et al., 2005). A possible explanation
of this phenomenon could be the involvement of 5HT2A receptors
and the disruption of the interaction of serotonin and dopamine
within the cortico-striato-thalamocortical loops (Kapur and Rem-
ington, 1996). However, data from a recent genetic association
study also suggested a glutamate involvement inAPP-inducedOCS
(Kwon et al., 2009).
A randomized double-blind study comparing olanzapine with
risperidone in patients with early psychosis found a difference in
Y-BOCS scores decreases, with olanzapine showing more efficacy.
However, these results have several limitations because Y-BOCS
scores only decreased significantly in mild OCS (Y-BOCS> 10)
subgroup.
Therefore, the choice of antipsychotic treatment in schizo-
obsessive patients is still difficult and only a few trials specifically
investigated the treatment of OCS or OCD in schizo-obsessive
patients. However, interesting data are emerging from the use
of aripiprazole (the atypical antipsychotic with the higher D2 –
receptor affinity) and lamotrigine (an anticonvulsant inhibiting
glutamate release). Glick et al. (2008) conducted an open-label
6 week trial of aripiprazole monotherapy in 15 schizophrenic
patients presenting OCS. Each patient switched from the ongoing
antipsychotic medication to aripiprazole monotherapy. At the end
of the trial six of the seven patients completing the study showed
an improvement on the Y-BOCS score of greater than 35% from
baseline to week 6.
Poyurovsky et al. (2010) conducted an 8weeks open-label trial
of lamotrigine augmentation in schizo-obsessive patients. Five of
nine study participant were responders to add-on lamotrigine
(≥35% reduction inY-BOCS score); theOCS-attenuating effect of
lamotrigine was not accompanied by improvement of schizophre-
nia symptoms supporting the notion that OCS are independent of
core schizophrenia symptoms in schizo-obsessive patients. Cur-
rent evidence supports the use of AAP in combination with an
SRI for the schizo-obsessive patients, but these findings are based
on a small sample sizes. The SRIs specifically recommended are
clomipramine, fluvoxamine, and sertraline (Berman et al., 1995b;
Poyurovsky and Weizman, 1998; Rahman et al., 1998; Reznik and
Sirota, 2000; Dwivedi et al., 2002).
OCD AND OTHER ANXIETY DISORDERS
Epidemiology
InDSM-IVOCDhas been classified as an anxiety disorder together
with PD, PTSD, and GAD. This nosological solution has not been
entirely satisfactory because of the peculiarity of OC phenom-
ena (Storch et al., 2008; Stein et al., 2010). However, the growing
evidence that OCD has much in common with other anxiety dis-
orders despite its specific features (Storch et al., 2008; Radua et al.,
2010; Stein et al., 2010) has led to the realization that it would be
inappropriate to remove it from the group of anxiety disorders in
DSM-5. This has dampened down the enthusiasm for obsessive–
compulsive spectrum disorders (OCSDs) as a separate diagnostic
group. As a result, the current proposal is to classify OCSDs along
with anxiety disorders to form a larger group tentatively called
“anxiety and OCSDs” (Taylor and Vaidya, 2009; Phillips et al.,
2010).
Lifetime comorbidity between OCD and other anxiety disor-
ders has been identified as 22% for specific phobia, 18% for social
anxiety disorder (social phobia), 12% for PD (Pigott et al., 1994),
and 30% forGAD. Therefore, it is clear that an accurate assessment
of OCD and anxiety comorbidities is necessary to achieve a proper
treatment and a good response to it.
Clinical characteristics, clinical course, and treatment
Panic disorder. The comorbidity between OCD and PD is
extremely high (13–56%). There are many similarities between
symptoms of OCD and PD, for example the hypochondriac polar-
ization and the excess of risk assessment that can be present in both
disorders. For some authors this fact can explain the effectiveness
of the same treatments for both disorders. Several evidences sug-
gested that CBT is effective in both OCD and PD. Thus, CBT
plus SSRI, can be an appropriate treatment when PD and OCD
are in comorbidity. Finally, increasing evidences indicate that the
γ-aminobutyric acid (GABA) system is important in the patho-
physiology of PD (Guttmacher et al., 1983). This could be a new
field for the treatment of comorbid PD in OCD.
Generalized anxiety. Generalized anxiety disorder is a current
and typically chronic mental disorder with prevalence in the gen-
eral population of around 6% (Murphy and Leighton, 2008). It is
characterized by inappropriate or excessive anxiety and worrying
that persists over time and is not restricted to a particular set of cir-
cumstances. The specific comorbidity of OCD and GAD in adults
is high, particularly among individuals with OCD. Both Andrews
et al. (1990) and reported over 30% of adults with OCD have a
lifetime history of GAD.
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The difficulty in distinguishing between the two disorders is
given by a considerable overlap between the worries in GAD and
the obsessions in OCD. Recent conceptualizations of GAD and
OCD have also emphasized the similarities between the func-
tions of worries in GAD and compulsions in OCD (Comer
et al., 2004), such as distortion of probabilistic thinking, risk
overvaluation, apprehensiveness. However, the two disorders are
generally distinguished by the fact that worries in GAD rep-
resent more excessive concerns about realistic situations, while
obsessions in OCD are considered to be alien to the individ-
ual (i.e., ego-dystonic) and more bizarre in nature (Barlow,
2002). Abramowitz and Foa found that OCD with comorbid
GAD was associated with higher rates of indecisiveness and
pathological responsibility among adults (Abramowitz and Foa,
1998).
Selective serotonin reuptake inhibitors are effective in both
disorders; however, if there is an unsatisfactory clinical response
several studies support the use of other drug augmentations.
Aliyev andAliyev (2008) demonstrated the efficacy of Valproate
for themanagement of GAD in a double-blind,placebo-controlled
randomized trial involving 80 male patients. Thus, valproate plus
SSRIs can be a good augmentation strategy inOCD/GADpatients.
Furthermore, AAP are known to be effective in the treatment of
resistant OCD. The addition of an atypical antipsychotic [low-
dose risperidone (Brawman-Mintzer et al., 2006) or olanzapine
augmentation of fluoxetine (Pollack et al., 2006)] in GAD patients
whodonot respond adequately tofirst line treatmentsmayprovide
additional benefit. Thus, the atypical antipsychotic augmentation
of an SSRI in an OCD/GAD patient may represent a more effective
treatment.
Finally, several trials suggested that Gabapentin and Pregabalin
(Rickels et al., 1990; Feltner et al., 2003) are both effective in
treating GAD. Our opinion is that they can be a good associa-
tion therapy with an SSRI in treating an OCD patient with GAD
comorbidity.
Post-traumatic stress disorder. Post-traumatic stress disorder
and OCD share several common elements in symptomatol-
ogy. Both are characterized by repeated intrusive thoughts; both
include avoidant behavior that severely interferes with daily func-
tioning and is directed by the need to avoid any cue, object, or
place that causes distress. Both involve compulsions that are per-
formed inorder to reduce anxiety (de Silva andMarks,1999,2001).
From an etiological perspective, both PTSD and OCD are associ-
ated with classical conditioning to an anxiety-provoking stimulus;
this connection between stimulus and anxiety, in turn, is rein-
forced by behaviors that reduce anxiety (de Silva and Marks, 1999;
Zohar et al., 2009). Many studies have attempted to explore the
link between trauma and OCD symptoms. Recently, Zohar et al.
described a case series of five Israeli veterans who were diagnosed
with both PTSD and OCD following combat trauma (Zohar J.
2011, Personal Communication). In this case series the content of
the obsessions was quite different from the intrusive symptoms
of PTSD. The thoughts, flashbacks, or psychological distress in
response to reminders of the trauma in PTSD were different from
the general obsessive thoughts at the OCD side of the diagnosis,
which included fear of contamination, disgust of dirt, and doubt.
Moreover, in this case series, the generalized OCD cues were typ-
ical of OCD (e.g., garbage, excessive washing, public toilets, etc).
Similarly, the compulsions were typical of OCD (e.g., washing and
checking, and unrelated to the trauma). Thus, the authors argued
that the course of the symptoms suggests a potential environ-
mental role in the development of OCD following an exposure to
traumatic event, suggesting a biological linkage between exposure
to trauma and OCD.
In conclusion, there is a clear need for specific and accurate
assessment of an OCD patient with another anxiety disorder in
order to start a more specific and effective treatment.
OCD AND NEUROLOGICAL DISEASES
Anxiety disorders frequently occur in individuals with neurologic
illnesses. Anxiety may be a symptom of a reaction to a neuro-
logic disorder, a medication side effect, or a comorbid condition.
The most common anxiety disorders seen in neurologic patients
are PD, GAD, social phobia, and OCD. Very often, these condi-
tions are unrecognized (and therefore untreated) or are attributed
to being a normal response to having a neurologic illness. How-
ever, if they are not treated, anxiety disorders can significantly
increase morbidity and mortality in neurologic patients (Davies
et al., 2001).
Obsessive–compulsive disorder has for long been associated
with epilepsy. Particularly, 10–22% of patients with temporal
lobe epilepsy (TLE) may have OCD. These patients show a high
rate of obsessions of washing, symmetry/exactness, and ordering,
with greater preoccupation concerning certain aspects of religion,
compared with controls or patients with idiopathic generalized
epilepsy. Furthermore,discrete anatomic lesions in these pathways,
or their surgical removal, may induce (or conversely) improve
OCD in TLE patients (Kaplan, 2010).
Obsessive–compulsive disorder is frequently described in
patients with primarily basal ganglia dysfunction, such as
Tourette’s syndrome, Sydenham’s chorea, Huntington’s disease,
and vonEconomo’s encephalitis (Miguel et al., 1997). Several stud-
ies found a high prevalence of OCS and OCD also in Parkinson’s
disease, but some others did not (Maia et al., 2003; Harbishet-
tara et al., 2005). Furthermore, Pallanti et al. (2010) described
the onset of a complex repetitive behavior (defined as “pound-
ing”) after bilateral subthalamicnucleus stimulation inParkinson’s
patients. Pounding has been interpreted as a compulsive behavior
and is defined as a stereotypic motor behavior characterized by an
intense fascination with repetitive purposeless movements, such
as taking a part mechanical objects, handling common objects as
if they were new and entertaining and continuously picking at
oneself, etc.
An acute onset of OCD may occur after stroke injury. This
kind of OCD onset has been associated with inferior parietal
(Simpson and Baldwin, 1995), basal ganglia (Carmin et al., 2002),
orbitofrontal (Kim and Lee, 2002), caudate (Thobois et al., 2004),
and posterior frontal (Swoboda and Jenike, 1995) infarcts and
traumatic orbitofrontal lesions (Ogai et al., 2005), further impli-
cating these structures in the pathogenesis of OCD. However, a
recent study reported a case of a patient suffering with severe OCD
whose symptoms disappeared immediately following a small right
posterior fronto-parietal infarct.
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Post-streptococcal autoimmunity is hypothesized tobe an addi-
tional etiologic pathway in a subset of children with OCD and tic
disorders (Swedo et al., 1998). This subset of children experiences a
sudden onset of OCD and/or motor tics in association with Group
A streptococcal (GAS) infections (e.g., “strep throat”), a disor-
der classified as pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections (PANDAS). Although the
clinical presentation of PANDAS was described over 10 years ago
by Swedo et al. (1998), it still remains controversial because a direct
evidence of a distinct pathogenic mechanism has yet to be found
in human studies.
Roughly one-third to one-half of children with Tourette syn-
drome (TS) or chronic tic disorder will experience comorbidOCD
throughout their lifetime (Bloch et al., 2006a). OCD symptoms in
patients with TS have an onset around the time that the tics reach
their worst-ever, but symptoms may also appear de novo in adult-
hood. OCD patients with comorbid tics tend to have greater rates
of symmetry obsessions, and counting, repeating, ordering, and
arranging compulsions than OCD patients without comorbid tic
symptoms (Leckman et al., 1994). In terms of pharmacotherapy,
children with OCD and comorbid tics are likely to have a worse
response to SSRIs than children without comorbid tics (March
et al., 2007). While children with OCD and comorbid tics may
not respond optimally to SSRIs, it has been shown that children
with OCD, with and without comorbid tics, appear to have a
similar response to cognitive behavioral therapy (March et al.,
2007). Another treatment option for OCD patients with comor-
bid tics is antipsychotic medication. A meta-analysis of antipsy-
chotic augmentation trials for treatment refractory OCD suggests
that OCD patients with comorbid tics may have an improved
response to this intervention (Hollander et al., 1991; Bloch et al.,
2006b).
Obsessive–compulsive disorder – attention deficit hyperactivity
disorder
Compulsivity and impulsivity are defined the former as the feeling
of being forced to perform certain action in order to relieve stress
or anxiety and the latter as the proneness to act without adequate
forethought. At first glance they may be considered as two oppo-
site behavioral features, but actually seem to be closely related in
certain clinical entities. Pathological gambling or substance abuse
disorders can be considered as an example: classically considered
as highly impulsive diseases, they both share compulsive features.
From this perspective, the frequent comorbidity between OCD
and ADHD is not surprising, and probably suggests an overlap in
their neurobiological underpinnings.
Attention deficit hyperactivity disorder is a common
childhood-onset neurodevelopmental disorder that occurs in
approximately 5% of the population, which frequently co-occurs
with OCD (Faraone et al., 2003). This relationship is of interest
for several reasons:
(1) Due to the fact that both of the two conditions may present
symptoms of inattention, differentiating between primary atten-
tive symptoms and attentive symptoms secondary to anxiety
disorders is of crucial relevance for prognosis, and treatment (de
Geus et al., 2007).
(2) The evidence that ADHD and OCD are frequently comorbid
with TS (de Geus et al., 2007), suggests that these three disor-
ders may be etiologically related (Comings and Comings, 1985;
Kadesjo and Gillberg, 2000; Gaze et al., 2006).
(3) Family studies suggest that OCD and ADHD may co-
segregate in families, and this could be useful in correctly
diagnosing a disorder (Geller et al., 2007a,b).
The ADHD prevalence rate among OCD patients varies widely,
ranging from 0 to 51% (Geller et al., 2001; Jaisoorya et al.,
2003). This could be an effect of differences in data acquisi-
tion, sample size, age of participants, recruitment sources, and
inclusion/exclusion criteria in the considered studies.
As already noted, both OCD and ADHD are highly comorbid
with TS, a tic disorder with a prevalence of 0.5–1% (Gaze et al.,
2006; Stewart et al., 2009).
Patients with the attentive subtype of ADHD (also calledADD)
frequently develop compulsive coping styles. They very often do
not have a complete overview of tasks and try tomanage confusion
and disorganization using extra control. The clinician should try
to differentiate a perfectionist coping style from an OCD. A way
of doing it could be to ask the patient what will happen if control
cannot be performed. If irritation arises, it is more likely to be
ADHD; if there is anxiety or panic, OCD should be considered
first (Kooij, 2010).
In a recent study Sheppard et al. (2010) found a higher rate of
ADHD in a sample of individuals with childhood-onsetOCD than
in the general ADHD population sample; the strongest associa-
tion was found betweenADHD and clinically significant hoarding
behavior. Hoarding is defined as the excessive acquisition and
failure to discard worthless items as they accumulate, leading to
distress or impairment, including the inability to use work or
living spaces (Frost and Gross, 1993; Steketee and Frost, 2005;
Iervolino et al., 2009; Mueller et al., 2009). Prevalence rates range
from 18 to 40%, and hoarding seems to occur in many psychiatric
conditions, in particular OCD (Frost et al., 1996). In Sheppard’s
study in total, 41.9% of participants with ADHD also had hoard-
ing behaviors compared to the 29.2% of participants without
ADHD.
CONCLUSION
Current research on animal and human models suggests that the
discovery of more precise anddistinctive neurofunctional targets is
possible and that may successfully lead to a patient-tailored treat-
ment algorithm. Identifying the different groups of patients and
basing the treatment on reliable and easily detectable neurodys-
functional targets is one of the most desirable and exciting goals
that in the next future may be achieved, in order to offer a highly
specific treatment for each single patient.
In the next years neuroscientific researches will provide a better
definition of the dysfunction implicated in the pathophysiology
of OCD. This process will improve the definition of different neu-
rodysfunctional treatment targets. Thus, the treatment of OCD
and of its comorbidities will become more neurodysfunctional
guided.
Another important goal will probably be the possibility
to differentiate between the simple co-occurrence of two or
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more syndromes and a real comorbidity, that represent two
distinct clinical situations, in order to explain why different
OCD sub-groups show different comorbidities patterns. This
may be due to the relationship between the neurobiological
underpinnings of OCD and of its comorbid conditions, which
could have a consistent overlap. As an example, it can be
hypothesized that the sub-group of OCD patients with affective
disorders comorbidity could have pathophysiological mecha-
nisms that are different from that of OCD/tic disorders sub-
group, therefore allowing us to exclude the concept of simple
co-occurrence.
However, this is an operation that in our opinion should be sub-
stantiated by strong and accurate biological evidences, and further
research is needed in the field.
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